
Johnson & Johnson Seeks FDA Approval for TREMFYA in Treating Crohn’s Disease
SPRING HOUSE, PA — Johnson & Johnson (NYSE: JNJ) has submitted a supplemental Biologics License Application (sBLA) to the U.S. Food and Drug Administration (FDA) for the approval of TREMFYA® …
Johnson & Johnson Seeks FDA Approval for TREMFYA in Treating Crohn’s Disease Read More